Observational cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients and two control groups: one with influenza pneumonia and the other with no viral pneumonia.
COVAPID is a multicenter cohort study with two retrospective control groups. No intervention
will be performed in included patients, only patient characteristics and data on VA-LRTI will
be collected.
Patients with confirmed SARS-CoV-2 community-acquired pneumonia, admitted to the
participating ICUs from the start of COVID epidemic will be eligible for this study. Those
admitted before the beginning of this study will be included retrospectively, and those
admitted after the beginning of the study will be included prospectively. 10-20 patients per
center will be included in this group. SARSCoV2 infection will be confirmed by a
nasopharyngeal PCR or respiratory secretions (tracheal aspirate or bronchoalveolar lavage)
PCR. Two retrospective groups will be constituted in order to give some insight of potential
impact of SARS-CoV2 infection on the incidence of VALRTI :1) Influenza group : patients with
influenza (A or B) community-acquired pneumonia. All patients with influenza community
acquired pneumonia and admitted in the same ICU will be eligible in this group.
The number of patients included in this group per center will be similar as that of patients
included in the SARS-CoV-2 pneumonia group (10-20 patients). These consecutive patients will
by identified using the files of Virology Lab. The first included patient will be the last of
the current influenza season (2019-2020), and others will be taken consecutively back to 2019
of 2018 if necessary. PCR (nasopharyngeal or respiratory secretions) confirmation of
influenza (A ou B) is required for patients in this group. 2) No viral infection group:
patients with no viral community acquired pneumonia. All patients receiving invasive
mechanical ventilation for more than 48h before COVID epidemic, for any reason other than
viral pneumonia are eligible for this group. The number of included patients in this group
will be similar as that of patients included in the SARS-CoV-2 group in the same center
(10-20 patients) These consecutive patients will be included starting at the end of January
2020 and going back to 2019 if necessary. VAT and VAP are defined using clinical,
radiological and quantitative microbiological criteria.
Inclusion Criteria:
For all three groups:
- Major patient
- In patients in ICU
- Patients intubated and mechanically ventilated for more than 48 hours.
For the SARS-CoV2 group: community-acquired SARS-CoV2 pneumonia For the influenza group:
community-acquired influenza pneumonia For the "No Viral Infection" group: no viral
pneumonia on admission.
Exclusion Criteria:
- Refusal to participate
- Lack of social security coverage
Hôpital Roger Salengro, ICU, CHU Lille
Lille, France
Saad Nseir, MD,PhD, Principal Investigator
University Hospital, Lille